QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
QIAGEN announced a new commercial partnership and co-marketing agreement with ID Solutions to expand the availability of dPCR assays for oncology research applications.
Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN’s QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA (cfDNA) from plasma and genomic DNA (gDNA) from formalin-fixed, paraffin-embedded (FFPE) tissue. QIAGEN will commercialize these kits starting in Europe as the first region, with the potential for future expansion into other regions.
This agreement supports QIAGEN’s strategic focus on accelerating the adoption of the QIAcuity dPCR platform in oncology research. The new assays expand QIAGEN’s portfolio, complementing the existing PanCancer Kits for detecting multiple hallmark mutations in DNA from diverse sample types and over 200 LNA (locked nucleic acid) Mutation Assays available via its GeneGlobe platform. This platform integrates pre-designed assays with a database of more than 10,000 biological entities, including genes, miRNAs, pathogens and pathways.
The partnership aligns with ID Solutions mission to develop its assays for research use only on fully integrated platforms.
For customers, this partnership translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, expanding beyond the current menu, enabling results in less than a day and meeting the growing demand for deeper molecular insights.
To learn more about QIAGEN’s dPCR solutions and the new assays available through this partnership, visit https://www.id-solutions.fr/en/idnaptex-range/.
